Dennis Patrick Molnar
Operationeel Directeur bij Apnimed, Inc.
Profiel
Dennis Patrick Molnar is currently a Non-Executive Director at Helperby Therapeutics Group Ltd.
and the Chief Operating Officer & Director at Apnimed, Inc. In the past, he worked as a Finance Director at Genaera Corp.
from 1998 to 2000, as well as held positions as a Director at Paratek Pharmaceuticals, Inc., President at JBI, and Principal at Bogart Delafield Ferrier LLC.
Molnar received his undergraduate degree from Brown University and an MBA from the University of Pennsylvania in 1998.
Actieve functies van Dennis Patrick Molnar
Bedrijven | Functie | Begin |
---|---|---|
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | Operationeel Directeur | - |
Helperby Therapeutics Group Ltd.
Helperby Therapeutics Group Ltd. Miscellaneous Commercial ServicesCommercial Services Helperby Therapeutics Group Ltd. engages in the development of novel solutions to treat infectious diseases with new combinations of repurposed approved drugs. The company was founded by Anthony Milnes Coates in 2002 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | 20-06-2018 |
Eerdere bekende functies van Dennis Patrick Molnar
Bedrijven | Functie | Einde |
---|---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Financieel Directeur/CFO | 01-01-2000 |
Bogart Delafield Ferrier LLC | Corporate Officer/Principal | - |
JBI | President | - |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Opleiding van Dennis Patrick Molnar
Brown University | Undergraduate Degree |
University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
JBI | Distribution Services |
Bogart Delafield Ferrier LLC | |
Helperby Therapeutics Group Ltd.
Helperby Therapeutics Group Ltd. Miscellaneous Commercial ServicesCommercial Services Helperby Therapeutics Group Ltd. engages in the development of novel solutions to treat infectious diseases with new combinations of repurposed approved drugs. The company was founded by Anthony Milnes Coates in 2002 and is headquartered in London, the United Kingdom. | Commercial Services |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | Health Technology |